Haowen Jiang,Sarah Jane Tiche,Clifford JiaJun He,Mohamed Jedoui,Balint Forgo,Meng Zhao,Bo He,Yang Li,Albert M. Li,Anh T. Truong,Jestine Ho,Cathyrin Simmermaker,Yanan Yang,Meng-Ning Zhou,Zhen Hu,Daniel J. Cuthbertson,Katrin J. Svensson,Florette K. Hazard,Hiroyuki Shimada,Bill Chiu,Jiangbin Ye

Abstract:Neuroblastoma is a leading cause of death in childhood cancer cases. Unlike adult malignancies, which typically develop from aged cells through accumulated damage and mutagenesis, neuroblastoma originates from neural crest cells with disrupted differentiation. This distinct feature provides novel therapeutic opportunities beyond conventional cytotoxic methods. Previously, we reported that the mitochondrial uncoupler NEN (niclosamide ethanolamine) activated mitochondria respiration to reprogram the epigenome, promoting neuronal differentiation. In the current study, we further combine NEN with retinoic acid (RA) to promote neural differentiation both and . The treatment increased the expression of RA signaling and neuron differentiation-related genes, resulting in a global shift in the transcriptome towards a more favorable prognosis. Overall, these results suggest that the combination of a mitochondrial uncoupler and the differentiation agent RA is a promising therapeutic strategy for neuroblastoma.

Mitochondrial uncoupler and retinoic acid synergistically induce differentiation and inhibit proliferation in neuroblastoma